Compare HDSN & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HDSN | TLSI |
|---|---|---|
| Founded | 1991 | 2010 |
| Country | United States | United States |
| Employees | N/A | 102 |
| Industry | Industrial Specialties | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 239.9M | 270.2M |
| IPO Year | 1996 | N/A |
| Metric | HDSN | TLSI |
|---|---|---|
| Price | $5.50 | $3.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $9.00 | $7.00 |
| AVG Volume (30 Days) | 594.2K | ★ 743.8K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $237,118,000.00 | N/A |
| Revenue This Year | $2.51 | $35.45 |
| Revenue Next Year | $2.38 | $37.58 |
| P/E Ratio | $527.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.64 | $2.20 |
| 52 Week High | $10.52 | $7.95 |
| Indicator | HDSN | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 51.94 | 43.50 |
| Support Level | $4.64 | $2.20 |
| Resistance Level | $6.49 | $5.41 |
| Average True Range (ATR) | 0.21 | 0.32 |
| MACD | 0.07 | 0.03 |
| Stochastic Oscillator | 96.07 | 71.05 |
Hudson Technologies Inc is an American industrial products manufacturer. It develops products which are mainly used in commercial air conditioning, industrial processing, and refrigeration systems. The company products include refrigerant and industrial gases, refrigerant management services and RefrigerantSide services, which consist of system decontamination. These are performed at customer's site using its Zugibeast system, which is a fast and portable system and allows the R-Side services team to accelerate critical services while saving customers time, money and aggravation. The company also owns a web-based real-time monitoring service which is used in the facility's refrigeration systems and other energy systems.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.